Hospital
Conway Community Services
Conway Community Services was paid $4.12M by Medicaid between Jan 2018 and Dec 2024, across 177 billing codes. Its largest line is 0241U, Neonatal screening for hereditary disorders, genomic sequence analysis panel — 12% of everything it billed.
33Billing provider infoCONWAY COMMUNITY SERVICES
CONWAY, AR 72032
CONWAY, AR 72032
33aNPI1285005140assigned 10/16/2015
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.12M
24GClaims269,513
24DCodes billed177
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#19 of 49
Median peer was paid$2.62M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WELLS, TROY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,654 | $428K | |
| 2019 | 47,321 | $545K | |
| 2020 | 35,673 | $462K | |
| 2021 | 42,462 | $805K | |
| 2022 | 39,758 | $732K | |
| 2023 | 38,359 | $651K | |
| 2024incomplete | 26,286 | $496K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 12% | 4,151 | 3,898 | $492K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 10% | 2,937 | 2,694 | $414K |
| 70450 | Computed tomography, head or brain; without contrast material | 7.1% | 3,263 | 2,945 | $294K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.6% | 3,122 | 2,739 | $270K |
| 80048 | Basic metabolic panel (calcium, ionized) | 6.1% | 13,406 | 11,124 | $249K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 3.8% | 704 | 595 | $156K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.1% | 1,022 | 935 | $129K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.8% | 487 | 470 | $114K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.5% | 10,152 | 8,564 | $103K |
| 36415 | Collection of venous blood by venipuncture | 2.2% | 19,811 | 16,782 | $91K |
| 80053 | Comprehensive metabolic panel | 2.1% | 4,552 | 4,005 | $86K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.9% | 1,140 | 1,045 | $77K |
165 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 1,156 | $70K |
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 3,821 | $68K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 9,328 | $65K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 1,570 | $62K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 609 | $61K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.4% | 498 | $57K |
| 85027 | 1.4% | 9,235 | $57K | |
| 80076 | 1.2% | 3,918 | $48K | |
| 81025 | 1.2% | 5,598 | $48K | |
| 87631 | 1.1% | 585 | $47K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 961 | $47K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.1% | 1,025 | $44K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,882 | $37K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,960 | $36K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 3,160 | $34K |
| 84484 | <1% | 4,972 | $33K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,652 | $30K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,574 | $30K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 158 | $29K |
| 81001 | <1% | 7,396 | $25K | |
| 83690 | <1% | 3,591 | $24K | |
| 87486 | <1% | 487 | $24K | |
| 87581 | <1% | 487 | $24K | |
| 86901 | <1% | 1,110 | $24K | |
| 82962 | <1% | 2,896 | $23K | |
| 80305 | <1% | 1,479 | $21K | |
| 86900 | <1% | 1,094 | $19K | |
| 73630 | <1% | 640 | $18K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 441 | $17K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,340 | $17K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,068 | $17K |
| 87088 | <1% | 1,959 | $16K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,205 | $15K |
| 80061 | Lipid panel | <1% | 1,130 | $15K |
| 72100 | <1% | 646 | $15K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 167 | $14K |
| 83880 | <1% | 720 | $14K | |
| 82077 | <1% | 782 | $14K | |
| 83605 | <1% | 1,470 | $13K | |
| 80143 | <1% | 652 | $13K | |
| 80179 | <1% | 644 | $12K | |
| 93975 | <1% | 155 | $12K | |
| 80320 | <1% | 846 | $12K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,663 | $11K |
| 87040 | <1% | 1,010 | $10K | |
| 99283 | Emergency room visit (moderate) | <1% | 1,524 | $10K |
| 81003 | <1% | 4,113 | $10K | |
| 80329 | <1% | 853 | $10K | |
| 96376 | <1% | 1,089 | $10K | |
| 82947 | <1% | 1,108 | $10K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,410 | $10K |
| 72141 | <1% | 44 | $10K | |
| 76000 | <1% | 194 | $10K | |
| 99284 | Emergency room visit (serious) | <1% | 1,974 | $9K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 31 | $9K |
| 73130 | <1% | 318 | $9K | |
| 73560 | <1% | 337 | $8K | |
| 85610 | <1% | 2,975 | $8K | |
| 85730 | <1% | 2,019 | $8K | |
| 73610 | <1% | 416 | $8K | |
| 87077 | <1% | 695 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,893 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,569 | $7K |
| 84703 | <1% | 644 | $7K | |
| 85055 | <1% | 412 | $7K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 47 | $7K |
| 80051 | <1% | 279 | $7K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 39 | $6K |
| 73030 | <1% | 246 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 639 | $5K |
| 71020 | <1% | 388 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,408 | $5K |
| 80306 | <1% | 300 | $5K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 128 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 100 | $4K |
| 83735 | <1% | 669 | $4K | |
| 82550 | <1% | 685 | $4K | |
| 85379 | <1% | 419 | $4K | |
| 82248 | <1% | 711 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 307 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 204 | $3K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 168 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $3K |
| 86850 | <1% | 890 | $3K | |
| 82565 | <1% | 663 | $3K | |
| 90715 | <1% | 199 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,216 | $3K |
| 12001 | <1% | 13 | $2K | |
| 71010 | <1% | 353 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,045 | $2K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 115 | $2K |
| 80050 | General health panel | <1% | 69 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,082 | $2K |
| 87186 | <1% | 256 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 395 | $1K |
| 93458 | <1% | 24 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 321 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 91 | $1K |
| 94760 | <1% | 90 | $1K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 56 | $1K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,440 | $902.20 |
| 74018 | <1% | 53 | $895.85 | |
| 74019 | <1% | 44 | $879.81 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 49 | $822.91 |
| 72040 | <1% | 48 | $744.95 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,324 | $719.95 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 17 | $708.70 |
| 0225U | <1% | 295 | $682.89 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 16 | $672.00 |
| 73110 | <1% | 46 | $653.14 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 17 | $636.46 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,108 | $628.56 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,246 | $614.21 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,152 | $601.67 |
| 87070 | <1% | 27 | $572.77 | |
| 73502 | <1% | 32 | $540.46 | |
| 84520 | <1% | 183 | $522.78 | |
| 93017 | <1% | 24 | $408.09 | |
| 85007 | <1% | 125 | $374.66 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 14 | $360.00 |
| 86780 | <1% | 16 | $325.58 | |
| 73070 | <1% | 13 | $314.10 | |
| 84100 | <1% | 71 | $298.96 | |
| 84702 | <1% | 24 | $290.31 | |
| 87807 | <1% | 24 | $273.21 | |
| J1815 | Injection, insulin, per 5 units | <1% | 282 | $248.61 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 831 | $217.26 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 282 | $211.29 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 17 | $182.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 584 | $161.61 |
| 94729 | <1% | 12 | $144.60 | |
| 82247 | <1% | 23 | $136.23 | |
| 81015 | <1% | 117 | $126.94 | |
| 83615 | <1% | 14 | $112.19 | |
| 87205 | <1% | 27 | $103.70 | |
| 99285 | Emergency room visit (most serious) | <1% | 27 | $95.91 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 30 | $95.41 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 59 | $87.57 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 292 | $82.94 |
| 82570 | <1% | 14 | $73.90 | |
| 84156 | <1% | 17 | $73.50 | |
| 99152 | <1% | 225 | $59.98 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 238 | $55.78 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 109 | $54.99 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 228 | $37.05 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,350 | $18.63 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 17 | $12.15 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 38 | $5.28 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 82 | $4.98 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 753 | $2.21 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,628 | $1.82 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 642 | $1.60 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 15 | $1.10 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,548 | $0.16 |
| A9270 | Non-covered item or service | <1% | 4,587 | $0.03 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 76 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 2,339 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 18 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 29 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 46 | $0.00 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 16 | $0.00 |
| J3490 | Unclassified drugs | 0% | 22 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 1,268 | $0.00 |
| 93356 | 0% | 109 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 362 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWELLS, TROY (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Baptist Health Regional Hospitals | Fort Smith, AR | $17.49M |
| Baptist Health | Little Rock, AR | $16.48M |
| Baptist Health | North Little Rock, AR | $14.02M |
| Baptist Health | Arkadelphia, AR | $4.82M |
| Baptist Health | Heber Springs, AR | $3.69M |
| Baptist Health Hospitals | Stuttgart, AR | $2.97M |
| Baptist Health | Little Rock, AR | $2.93M |
| Baptist Health | Malvern, AR | $2.68M |
| Baptist Health Regional Hospitals | Van Buren, AR | $2.46M |
| Baptist Health | Little Rock, AR | $1.83M |
| Baptist Health | Arkadelphia, AR | $1.51M |
| Baptist Health Hospitals | Stuttgart, AR | $901K |
| Baptist Health | Little Rock, AR | $780K |
| Baptist Health | North Little Rock, AR | $411K |
| Baptist Health | Monticello, AR | $367K |
| Baptist Health | Conway, AR | $142K |
| Baptist Health | Little Rock, AR | $88K |
| Baptist Health | Prescott, AR | $33K |
| Baptist Health | Malvern, AR | $31K |
| Baptist Health | Heber Springs, AR | $22K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.